Healthesystems is attending the Wisconsin Workers’ Compensation Forum, which brings together professionals in workers’ comp.
Healthesystems is attending the International Association of Industrial Accident Boards and Commissions Convention, which addresses policy, regulatory, and administrative challenges and opportunities affecting workers’ compensation.
Approval Date: Aug 2025
A GLP-1 receptor antagonist, this drug is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or who are overweight with at least one weight-related comorbidity. This is the first generically available GLP-1 receptor agonist for the treatment of obesity.
Approval Date: Jul 2025
A muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Approval Date: Jul 2025
An NSAID indicated for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
Approval Date: Jul 2025
Indicated alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension or coronary artery disease
Approval Date: Jul 2025
Indicated for the treatment of hypertension to lower blood pressure, in patients 55 and older to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, and in patients with post-myocardial infarction heart failure to reduce risk of death and hospitalization
Approval Date: Jul 2025
Indicated to improve glycemic control in patients with diabetes mellitus
Approval Date: Jun 2025
Indicated as an adjunct to diet and exercise to improve glycemic control for the treatment of type 2 diabetes
Approval Date: Jun 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns
Approval Date: May 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns. In March, a 2.5 mg dose of this generic was approved; this approval applies to 10 mg, 15 mg, and 20 mg doses
Approval Date: May 2025
Indicated as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy.
Approval Date: May 2025
While DHE has been available since 1946, this is the first DHE drug available in a ready-to-use autoinjector, indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches
Approval Date: May 2025
Indicated for the treatment of pulmonary arterial hypertension, this is the first and only dry-powder formulation of treprostinil
Approval Date: May 2025
A biosimilar to Stelara (ustekinumab), this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severely active Crohn’s disease, and moderate to severely active Ulcerative Colitis
Approval Date: Apr 2025
While DHE has been available since 1946, this is the first DHE drug available in a nasal powder formulation and indicated for the acute treatment of migraine with or without aura
Approval Date: Mar 2025
Indicated for the treatment of hypertension, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic neuropathy in certain type 2 diabetes patients with hypertension
